

Vascular Grafts –Pipeline Insight and Competitive Landscape, 2022

<https://marketpublishers.com/r/VF9F67A14B9BEN.html>

Date: January 2022

Pages: 60

Price: US\$ 3,500.00 (Single User License)

ID: VF9F67A14B9BEN

Abstracts

This report can be delivered to the clients within 4-5 Business Days

DelveInsight's, "Vascular Grafts –Pipeline Insight and 2022," report provides comprehensive insights about 20+ companies and 25+ pipeline devices in Vascular Grafts pipeline landscape. Heart disease has been the world's biggest cause of mortality, with this trend forecast to continue into the near future. Common disorders contribute to blood vessel stenosis or occlusion. Surgeries using vascular grafts such as coronary artery bypass grafting and peripheral artery bypass grafting is the recommended treatment for long-term revascularization of occluded vessels. Over the past forty years, significant progress has been made in our perception of successful regeneration of the blood vessels, beginning with the inadequacies of early tissue-engineered vascular grafts engineered using isolated components or molecules, such as collagen gels. In the coming years, all these advancements will eventually lead to growth in the market.

Geography Covered

Global coverage

Vascular Grafts Overview

Vascular Grafts: Understanding

A vascular graft (also called vascular bypass) is a surgical procedure that redirects blood flow from one area of the body to another by reconnecting the blood vessels.

Vascular grafting is most commonly done to bypass a complete or partial blockage in an artery in order to improve blood flow to the organ or extremity supplied by the diseased artery. Vascular grafts are of different types based on the indication and raw materials used for the graft to suit the host tissue.

Vascular Grafts Devices Competitive Assessment

This segment of the vascular grafts devices pipeline report encloses its detailed analysis of various pipeline devices which include product description, licensing and collaboration details and other developmental activities including the latest news and press releases. The report also provides list of major players involved in the pipeline product development.

Product Raw Material

Vascular Grafts can be divided based on raw materials – Polyester Grafts, ePTFE, Polyurethane Grafts and Biosynthetic Grafts, which are covered in the report.

Product Indication

Vascular Grafts can be divided based on its application – Cardiac Aneurysms, Vascular Occlusion and Kidney Failure, which are covered in the report.

Major Players in Vascular Grafts

There are approx. 20+ key companies which are developing the products for Vascular Grafts.

NuSpun Vascular Graft: Biosurfaces Inc

NuSpun Vascular Graft is being developed by BioSurfaces which has completed initial preclinical trials. It has following features:

First synthetic, off-the-shelf, acellular graft with early access

Uses science of extracellular scaffold to promote tissue integration, which may improve clinical outcomes

Scalable, rapid, automated manufacturing process

Conducted extensive benchtop testing, initial biocompatibility studies and extended preclinical trials

Superior economics - faster to dialysis, less hospitalizations

RegenaVasc: RegenaGraft

RegenaVasc, developed by RegenaGraft is synthetic vascular repair and replacement for vascular (artery and vein) applications.

Further product details are provided in the report.....

Vascular Grafts Competitive Benchmarking

This segment of the reports provides analysis of the pipeline report to give a clear understanding of the comparative analysis.

The analysis is based on

Brand Positioning of Leading companies

Application

Industry Collaborations

Vascular Grafts: Commercialization Activity

This segment of the report provides a detailed list of any commercial activity in the field of vascular grafts ranging from collaboration, mergers and acquisition, recent breakthrough among others.

Development Activities

February 2020, Luo et al. generated vascular smooth muscle cells from human induced pluripotent stem cells and cultured them on biodegradable polyglycolic acid scaffolds exposed to pulsatile radial stress. When implanted into rats, these TEVGs showed high mechanical strength with no dilation, elongation, or wall thickening. Moreover, the TEVGs associated with limited thrombosis and showed no teratoma formation. Further optimization and engineering to limit immune rejection should provide cells and tissues suitable for treating injury or dysfunction of the cardiovascular system.

In the present study, carboxymethyl chitosan (CMC) and chitosan (CS) were chosen as the anti-thrombotic and anti-bacterial components, respectively; and then an asymmetric vascular graft was fabricated by co-electrospinning. The outer layer of the graft had a certain anti-bacterial effect owing to the addition of chitosan. Besides, the inner layer of the graft could greatly promote the growth of endothelial cells. It is believed that the asymmetric SDVG with anti-thrombotic and anti-bacterial functions could contribute to the future clinical implantation of tissue engineered vascular grafts.

Further commercial activities are provided in the report.....

Vascular Grafts: Reimbursement

US

The special control for this device is the FDA guidance document entitled 'Guidance Document for Vascular Prostheses 510(k) Submissions' under CFR - Code of Federal Regulations Title 21.

Further information is provided in the report.....

Report Highlights

Extensive coverage of the Vascular Grafts under development

The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

The report reviews the major players involved in the development of Vascular Grafts and list all their pipeline projects

The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

The report provides key clinical trial data of ongoing trials specific to pipeline products

Recent developments in the segment / industry

The report consists of in depth analysis of pipeline products based on various parameters

Vascular Grafts Report Insights

Vascular Grafts - Pipeline Analysis

Vascular Grafts - Unmet Need

Vascular Grafts - Market Dynamics

Vascular Grafts - Future Perspectives and Conclusion

Vascular Grafts - Analyst Views

Key Questions

What are significant companies in this segment, their information, analysis, and insights to improve R&D strategies?

How to identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage?

What are important and diverse types of Vascular Grafts under development?

What are market-entry and market expansion strategies in Vascular Grafts?

What are some of the mergers and acquisitions and to identify major players with the most promising pipeline?

What is in-depth analysis of the product's current stage of development, territory and estimated launch date?

Key Players

RegenaGraft

Humacyte Inc

Innovia LLC

LeMaitre Vascular Inc

Merit Medical Systems Inc

Peca Labs Inc

PQ Bypass Inc

Secant Group LLC

Terumo Aortic Company

Tgen Tech LLC

TTK Healthcare Ltd

VenoStent Inc

VesselTek BioMedical

VESSL Therapeutics Ltd

Contents

1. KEY INSIGHTS

2. VASCULAR GRAFTS: SNAPSHOT

3. VASCULAR GRAFTS

- 3.1. Product Overview
- 3.2. Regulatory Approvals based on Class
- 3.3. Indications
- 3.4. Mechanism

4. VASCULAR GRAFTS: COMPETITIVE ASSESSMENT

- 4.1. Assessment by Product Raw Material
 - 4.1.1. Polyester Grafts
 - 4.1.2. ePTFE
 - 4.1.3. Polyurethane Grafts
 - 4.1.4. Biosynthetic Grafts
- 4.2. Assessment by Indication
- 4.3. Assessment by Company
 - 4.3.1. Biosurfaces Inc
 - 4.3.1.1. NuSpun Vascular Graft: Biosurfaces Inc
 - 4.3.1.1.1. Product Information
 - 4.3.1.1.2. Research and Development
 - 4.3.1.1.3. Patent Details
 - 4.3.1.1.4. Regulatory Milestone
 - 4.3.2. RegenaGraft
 - 4.3.2.1. RegenaVasc: RegenaGraft
 - 4.3.2.1.1. Product Information
 - 4.3.2.1.2. Research and Development
 - 4.3.2.1.3. Patent Details
 - 4.3.2.1.4. Regulatory Milestone

*More Companies and products would be added in the final report

5. VASCULAR GRAFTS: COMPETITIVE BENCHMARKING: BY COMPANY

- 5.1. Brand Positioning of Leading companies

- 5.2. Analysis based on Application
- 5.3. Analysis based on Industry Collaborations

6. VASCULAR GRAFTS – COMMERCIALIZATION ACTIVITY

- 6.1. Collaboration
- 6.2. Licensing
- 6.3. Merger and Acquisition
- 6.4. Recent Breakthroughs
- 6.5. Literature Studies
- 6.6. KOL Views

7. VASCULAR GRAFTS: REGULATORY

- 7.1. US
- 7.2. Europe
- 7.3. Japan

8. VASCULAR GRAFTS: REIMBURSEMENT

- 8.1. Case Study - US
- 8.2. Case Study - Europe
- 8.3. Case Study –Japan

9. VASCULAR GRAFTS: MARKET DYNAMICS

- 9.1. Unmet Needs
- 9.2. Market Drivers
- 9.3. Market Barriers

10. DELVEINSIGHT'S ANALYTICAL PERSPECTIVE

- 10.1. PEST Analysis
- 10.2. Future Growth Perspectives

11. CONCLUSION

12. APPENDIX

12.1. Research Methodology

12.1.1. Coverage

12.1.2. Secondary Research

13. BIBLIOGRAPHY

14. DELVEINSIGHT CAPABILITIES

15. DISCLAIMER

16. ABOUT DELVEINSIGHT

I would like to order

Product name: Vascular Grafts –Pipeline Insight and Competitive Landscape, 2022

Product link: <https://marketpublishers.com/r/VF9F67A14B9BEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/VF9F67A14B9BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970